These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 20332449)
1. The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice. Pourgholami MH; Cai ZY; Chu SW; Galettis P; Morris DL Anticancer Res; 2010 Feb; 30(2):423-8. PubMed ID: 20332449 [TBL] [Abstract][Full Text] [Related]
2. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879 [TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. Cai ZY; Galettis P; Lu Y; Morris DL; Pourgholami MH Anticancer Res; 2007; 27(1A):417-22. PubMed ID: 17352262 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. Li Z; Chen C; Ai D; Wang C; Li J; Qi Y; Yi W; Shen H; Cao J Environ Toxicol Pharmacol; 2012 Mar; 33(2):197-204. PubMed ID: 22227164 [TBL] [Abstract][Full Text] [Related]
6. Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice. Ehteda A; Galettis P; Chu SW; Pillai K; Morris DL Anticancer Res; 2012 Sep; 32(9):3659-66. PubMed ID: 22993303 [TBL] [Abstract][Full Text] [Related]
7. Dose-dependent activity of albendazole against benzimidazole-resistant nematodes in sheep: relationship between pharmacokinetics and efficacy. Moreno L; Echevarria F; Muñoz F; Alvarez L; Sanchez Bruni S; Lanusse C Exp Parasitol; 2004; 106(3-4):150-7. PubMed ID: 15172222 [TBL] [Abstract][Full Text] [Related]
8. Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. Gokbulut C; Akar F; McKellar QA Vet J; 2006 Jul; 172(1):166-72. PubMed ID: 16772142 [TBL] [Abstract][Full Text] [Related]
9. Disposition kinetics of albendazole and metabolites in laying hens. Bistoletti M; Alvarez L; Lanusse C; Moreno L J Vet Pharmacol Ther; 2013 Apr; 36(2):161-8. PubMed ID: 22533477 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. Pourgholami MH; Cai ZY; Wang L; Badar S; Links M; Morris DL Cancer Invest; 2009 Feb; 27(2):171-7. PubMed ID: 19235589 [TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252 [TBL] [Abstract][Full Text] [Related]
12. Comparative plasma disposition of fenbendazole, oxfendazole and albendazole in dogs. Gokbulut C; Bilgili A; Hanedan B; McKellar QA Vet Parasitol; 2007 Sep; 148(3-4):279-87. PubMed ID: 17673370 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of albendazole sulfoxide enantiomers administered in racemic form and separately in rats. Capece BP; Castells G; Godoy C; Arboix M; Cristòfol C Vet J; 2008 Aug; 177(2):297-9. PubMed ID: 17566773 [TBL] [Abstract][Full Text] [Related]
14. Albendazole sulphoxide kinetic disposition after treatment with different formulations in dogs. Dib A; Palma S; Suárez G; Farías C; Cabrera P; Castro S; Allemandi D; Moreno L; Lanusse C; Sánchez Bruni S J Vet Pharmacol Ther; 2011 Apr; 34(2):136-41. PubMed ID: 21395604 [TBL] [Abstract][Full Text] [Related]
15. Metabolism and depletion of albendazole in the muscle tissue of channel catfish following oral treatment. Shaikh B; Rummel N; Gieseker C; Reimschuessel R J Vet Pharmacol Ther; 2006 Dec; 29(6):525-30. PubMed ID: 17083456 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557 [TBL] [Abstract][Full Text] [Related]
17. Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice. Choi EK; Kim SW; Nam EJ; Paek J; Yim GW; Kang MH; Kim YT Reprod Sci; 2011 Aug; 18(8):763-71. PubMed ID: 21421899 [TBL] [Abstract][Full Text] [Related]
18. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Hashimoto K; Morishige K; Sawada K; Tahara M; Kawagishi R; Ikebuchi Y; Sakata M; Tasaka K; Murata Y Cancer Res; 2005 Jan; 65(2):540-5. PubMed ID: 15695397 [TBL] [Abstract][Full Text] [Related]
19. Differences in plasma and abomasal kinetics of albendazole and its metabolites in calves grazed on pasture or fed a grain-based diet. Sánchez S; Alvarez L; Pis A; Quiroga M; Lanusse C Res Vet Sci; 1999 Jun; 66(3):223-30. PubMed ID: 10333463 [TBL] [Abstract][Full Text] [Related]
20. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. Noorani L; Stenzel M; Liang R; Pourgholami MH; Morris DL J Nanobiotechnology; 2015 Mar; 13():25. PubMed ID: 25890381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]